Stockscreener 앱 받기
1.36
6.21%
-0.09
시간 외 거래:
1.36
전일 마감가:
$1.45
열려 있는:
$1.43
하루 거래량:
640.92K
Relative Volume:
0.58
시가총액:
$102.17M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.2996
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
-4.23%
1개월 성능:
+16.24%
6개월 성능:
-64.02%
1년 성능:
-88.39%
1일 변동 폭
$1.33
$1.45
1주일 범위
$1.325
$1.51
52주 변동 폭
$1.01
$13.24
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.36 | 102.17M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - Sete News
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Drug Development Team with Strategic New Hire Grant Worth $20,000 - Stock Titan
Was anything positive for Zentalis Pharmaceuticals Inc (ZNTL) stock last session? - uspostnews.com
Zentalis Pharmaceuticals Inc [ZNTL] Director makes an insider purchase of 21,000 shares worth 29373.0. - knoxdaily.com
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock By Investing.com - Investing.com Canada
Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock - Investing.com Australia
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Ratios Revealed: Decoding Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Health - DWinneX
Zentalis shares insights on cancer research at AACR - Investing.com Australia
Zentalis (ZNTL) Advances with Phase 2 Trial in Ovarian Cancer | - GuruFocus
Zentalis shares insights on cancer research at AACR By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial - marketscreener.com
Zentalis Doses First Patient In Phase 2 DENALI Trial Of Azenosertib In Cyclin E1+ PROC - Nasdaq
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Breakthrough: New Cancer Drug Achieves 35% Response Rate in Hard-to-Treat Ovarian Cancer Patients - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Geode Capital Management LLC - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Levi & Korsinsky Announces an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. (ZNTL) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Cerity Partners LLC Makes New $40,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) Has Seen A Fall Of -88.62% This Year, Is It Still A Better Option Than Others? – Marketing Sentinel - Marketing Sentinel
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Increased by Russell Investments Group Ltd. - Defense World
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Chief Medical Officer Bruns Ingmar acquire 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL] - knoxdaily.com
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - The Manila Times
Zentalis Pharmaceuticals Announces Poster Presentation at ASCO 2025 on Azenosertib for Colorectal Cancer - Nasdaq
New Clinical Data: Zentalis's Novel Cancer Drug Shows Promise in Metastatic Colorectal Cancer Treatment - Stock Titan
JPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Franklin Resources Inc. Buys Shares of 106,748 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Raymond James Financial Inc. Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
12,840 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Prudential Financial Inc. - Defense World
Sei Investments Co. Purchases Shares of 35,320 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL): Can The Stock Still Lose Despite An -61.39% YTD Loss? - Marketing Sentinel
Zentalis stock plunges to 52-week low at $1.08 amid market challenges - Investing.com Canada
Lost Money on Zentalis Pharmaceuticals, Inc.(ZNTL)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
Investor’s Delight: Zentalis Pharmaceuticals Inc (ZNTL) Closes Weak at 1.17, Down -8.95 - DWinneX
Thrivent Financial for Lutherans Grows Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World
What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):